Narval Bio

Company profile

Narval Bio company profile

Narval develops next-generation of antibody-like drugs using macrocyclic synthetic proteins that mimicthe activity of antibodies and can be delivered through mucosal tissues for localized treatment and non-systemic delivery. Our Antibody Mimetic Proteins, or AMP for short, are developed by fusing CDR3 regions of a single domain shark antibodies toa conoprotein scaffold from a sea snail, and we optimize their capabilities using AI and ML algorithms. Narval’s AMPs offer a breakthrough solution for fast, accessible, and deployable therapeutics in areas like pandemics, emergency outbreaks, biodefense, animal health, and agricultural biosecurity.